Skip to main content
. 2020 Apr 29;6(1):e001195. doi: 10.1136/rmdopen-2020-001195

Figure 2.

Figure 2

Forest plot of relative risk about the following outcomes. Remission rate at 6 months (A), antineutrophil cytoplasmic antibody negativity at 6 months (B) and relapse rate (C).